Compare Freeport-McMoRan Inc (FCX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Viatris Inc — how do they compare? Freeport-McMoRan Inc trades at $73 (market cap $103.19B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Freeport-McMoRan Inc is far larger — about 5.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.74%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Viatris Inc for 57 Days on average.
| FCX | VTRS | |
|---|---|---|
Market Cap | $103.19B | $20.12B |
Volume | 11,744,911 | 7,543,511 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $18.27 |
52-Week Low | $38.65 | $9.74 |
Typical Hold Time | 69 Days | 57 Days |
Enterprise Value | $109.47B | $32.24B |
Dividend Yield | 0.83% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.13, down 1.98% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $72.27. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong operating cash flow of $5.61 billion in 2025 supports ongoing expansion projects amid favorable copper demand trends.
The outlook for FCX is positive, driven by robust copper demand from AI and data center growth, but risks include rising production costs and a legal investigation. Wall Street sentiment is bullish with 61% buy ratings, though the stock faces near-term resistance at $72.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
